About this trial
The main aims of this study are to compare progression-free survival and overall survival between the two groups in this study.
Other aims of this study include comparing the overall response rate and duration of response to treatment between the two groups, and documenting side effects to treatment.
This study is open to men and women over 18 years of age with confirmed hepatocellular carcinoma (type of liver cancer). Patients cannot have had previous therapy for advanced or unresected hepatocellular carcinoma to be eligible to participate in this study.
Where’s this trial being run?St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Phase 3 randomized, double-blinded, active-controlled clinical study to evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab versus lenvatinib alone in first-line intervention of participants with unresectable hepatocellular carcinoma
|Principal Investigator:||Professor Ray McDermott|
Ireland: May 2019
|Global Recruitment Target:||600|
|Ireland Recruitment Target:||10|